Locations:
Search IconSearch
August 17, 2021/Neurosciences/Podcast

Neurosarcoidosis: Complexities in Its Differential Diagnosis and Care (Podcast)

Diagnosis and treatment depend on clinical manifestations, which vary widely

The clinical manifestations and course of sarcoidosis vary, in part because the tiny collections of granulomas associated with this chronic disease can occur in any part of the body. The most common manifestations of neurosarcoidosis, which affects approximately 5% of sarcoid patients, include cranial neuropathy, polycranial neuropathy and meningitis.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Conducting a systemic evaluation to find a biopsy target is essential when trying to diagnose sarcoidosis, says Brandon Moss, MD, a neurologist with Cleveland Clinic’s Mellen Center for Multiple Sclerosis who also sees patients in its Sarcoidosis Center. “As they say, tissue is the issue,” he notes, “so the main job is to try and get biopsy proof of granulomatous disease.”

In the newest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Moss discusses neurosarcoidosis, the complexity of its differential diagnosis and other management issues. He delves into:

  • The prevalence of sarcoidosis and typical patient population
  • Presentation and diagnosis of the chronic disease
  • The role of biomarkers in diagnosis and treatment response
  • Treatment approaches
  • The long-term prognosis for neurosarcoid patients

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Excerpt from the podcast

Dr. Moss: In terms of a gold standard for diagnosis for neurosarcoidosis, right now I think the most established is the Neurosarcoidosis Consortium Consensus Criteria for the Diagnosis of Sarcoidosis. These are largely based on the Zajicek criteria, which have been around for a much longer period of time. But essentially, everybody needs to have a clinical presentation and diagnostic evaluation that suggests neurosarcoidosis. And the diagnostic evaluation should include studies that are pertinent for that disease manifestation, whether it’s MRI, spinal fluid studies or EMG nerve conduction studies.

Advertisement

There should also be a thorough workup for mimics for everybody, to make sure you’re not missing some of these key players, which could also be in the differential diagnosis. After that, the diagnosis is dependent upon biopsy, and there are various levels of certainty depending upon whether or not you can get a biopsy showing granulomatous disease [see image below] and where the biopsy is. So people with possible sarcoidosis do not have biopsy evidence of granulomatous disease. People with probable neurosarcoidosis have biopsy evidence of sarcoidosis in a non-neural organ system. And people with definite neurosarcoidosis have biopsy proof of granulomatous disease within the nervous system.

An image of granuloma in meninges.

Pathology image showing a granuloma in the meninges, the key identifying feature of neurosarcoidosis.

Advertisement

Related Articles

Physical therapist helping patient walk with a powered exoskeleton and walker

Exoskeleton-Aided Physical Therapy Proves Feasible in MS

Study looked at mobility measures and safety

portrait of Dr. Kriti Bhayana against decorative background with podcast overlay
April 2, 2026/Neurosciences/Podcast

Practice Essentials for Pediatric and Perinatal Stroke (Podcast)

Types and presentation may differ from adults, but early recognition and intervention are just as key

Two-dimensional scatter plot of peak T1 versus T2 times from pre-extended lumbar drainage MRI

MR Fingerprinting Predicts Shunt Efficacy in NPH

Study tests potential for a more accurate treatment predictor

person going into a Gamma Knife machine for radiotherapy
March 25, 2026/Neurosciences/Brain Tumor

Predicting Response to Stereotactic Radiosurgery for Recurrent Glioblastoma

Study uses molecular and clinical stratification to help guide patient selection

illustration of human brain with rumor at top right
March 23, 2026/Neurosciences/Brain Tumor

Adding Eflornithine to Lomustine Extends Survival in Recurrent IDH-Mutant Grade 3 Astrocytoma

Phase 3 STELLAR trial underscores role of molecular stratification in glioma care

brain MRI taken from the back of the head
March 20, 2026/Neurosciences/Epilepsy

Unmasking the ‘Tethered’ Temporal Lobe: New MRI Metrics Improve Detection of Encephaloceles in Refractory Epilepsy

Early identification of temporal encephaloceles can improve surgical decision-making

brain scan with white lesion on right side

ARISE II Recommendations Chart a Course for Advancing Intracranial Hemorrhage Care

Academia, industry and government leaders develop consensus priorities

two brain scans side by side with a yellow circle on the left scan
March 13, 2026/Neurosciences/Epilepsy

SEEG Linked With More Complete Resection and Greater Seizure Freedom in MOGHE Subtype of Epilepsy

Insights from one of the first studies of invasive monitoring in the rare form of focal cortical dysplasia

Ad